Novel genera and species of coniothyrium-like fungi in Montagnulaceae (Ascomycota)

Autor: J B Stielow, Karolina Dukik, Markus Göker, G J M Verkley, R Renfurm

Publikováno v: Persoonia : Molecular Phylogeny and Evolution of Fungi
Persoonia, 32, 25-51. National Herbarium Nederland
Persoonia-Molecular Phylogeny and Evolution of Fungi, 32(1), 25-51

Based on analyses of concatenated internal transcribed spacer regions of the nrDNA operon (ITS), large subunit rDNA (LSU), γ-actin and β-tubulin gene sequences the taxonomy of coniothyrium-like fungi belonging in the family Montagnulaceae, order Pl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b8d3d4a8f1608dae93706b7d27c768d
https://doi.org/10.3767/003158514x679191

Tolerability of mirtazapine in a naturalistic patient setting

Autor: R. Renfurm, L. Timmerman, E. Vester

Publikováno v: Biological Psychiatry. 42:247S

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cab249bfdb7ed45d82150a873e0822c3
https://doi.org/10.1016/s0006-3223(97)87935-8

Efficacy and tolerability of mirtazapine in everyday clinical practice

Autor: E. Vester, L. Timmerman, R. Renfurm

Publikováno v: Biological Psychiatry. 42:247S

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1b7f587e7882310df765eda6152e7ebd
https://doi.org/10.1016/s0006-3223(97)87934-6

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Atrasentan in Patients with IgA Nephropathy.

Autor: Heerspink HJL; From the Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands (H.J.L.H.); the National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney (M.J.); the Division of Nephrology, University of Utah Health, Salt Lake City (D.E.K.); Stanford University, Stanford, CA (R.A.L.); the University of British Columbia, Vancouver, Canada (A. Levin); Mount Elizabeth Novena Hospital, Singapore (A. Liew); Peking University First Hospital, Beijing (H.Z.); Chinook Therapeutics, Seattle (T.G.); Novartis, East Hanover, NJ (A. Lodha, Y.W.); Novartis, Basel, Switzerland (R.R.); and the University of Leicester, Leicester, United Kingdom (J.B.)., Jardine M; From the Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands (H.J.L.H.); the National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney (M.J.); the Division of Nephrology, University of Utah Health, Salt Lake City (D.E.K.); Stanford University, Stanford, CA (R.A.L.); the University of British Columbia, Vancouver, Canada (A. Levin); Mount Elizabeth Novena Hospital, Singapore (A. Liew); Peking University First Hospital, Beijing (H.Z.); Chinook Therapeutics, Seattle (T.G.); Novartis, East Hanover, NJ (A. Lodha, Y.W.); Novartis, Basel, Switzerland (R.R.); and the University of Leicester, Leicester, United Kingdom (J.B.)., Kohan DE; From the Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands (H.J.L.H.); the National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney (M.J.); the Division of Nephrology, University of Utah Health, Salt Lake City (D.E.K.); Stanford University, Stanford, CA (R.A.L.); the University of British Columbia, Vancouver, Canada (A. Levin); Mount Elizabeth Novena Hospital, Singapore (A. Liew); Peking University First Hospital, Beijing (H.Z.); Chinook Therapeutics, Seattle (T.G.); Novartis, East Hanover, NJ (A. Lodha, Y.W.); Novartis, Basel, Switzerland (R.R.); and the University of Leicester, Leicester, United Kingdom (J.B.)., Lafayette RA; From the Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands (H.J.L.H.); the National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney (M.J.); the Division of Nephrology, University of Utah Health, Salt Lake City (D.E.K.); Stanford University, Stanford, CA (R.A.L.); the University of British Columbia, Vancouver, Canada (A. Levin); Mount Elizabeth Novena Hospital, Singapore (A. Liew); Peking University First Hospital, Beijing (H.Z.); Chinook Therapeutics, Seattle (T.G.); Novartis, East Hanover, NJ (A. Lodha, Y.W.); Novartis, Basel, Switzerland (R.R.); and the University of Leicester, Leicester, United Kingdom (J.B.)., Levin A; From the Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands (H.J.L.H.); the National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney (M.J.); the Division of Nephrology, University of Utah Health, Salt Lake City (D.E.K.); Stanford University, Stanford, CA (R.A.L.); the University of British Columbia, Vancouver, Canada (A. Levin); Mount Elizabeth Novena Hospital, Singapore (A. Liew); Peking University First Hospital, Beijing (H.Z.); Chinook Therapeutics, Seattle (T.G.); Novartis, East Hanover, NJ (A. Lodha, Y.W.); Novartis, Basel, Switzerland (R.R.); and the University of Leicester, Leicester, United Kingdom (J.B.)., Liew A; From the Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands (H.J.L.H.); the National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney (M.J.); the Division of Nephrology, University of Utah Health, Salt Lake City (D.E.K.); Stanford University, Stanford, CA (R.A.L.); the University of British Columbia, Vancouver, Canada (A. Levin); Mount Elizabeth Novena Hospital, Singapore (A. Liew); Peking University First Hospital, Beijing (H.Z.); Chinook Therapeutics, Seattle (T.G.); Novartis, East Hanover, NJ (A. Lodha, Y.W.); Novartis, Basel, Switzerland (R.R.); and the University of Leicester, Leicester, United Kingdom (J.B.)., Zhang H; From the Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands (H.J.L.H.); the National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney (M.J.); the Division of Nephrology, University of Utah Health, Salt Lake City (D.E.K.); Stanford University, Stanford, CA (R.A.L.); the University of British Columbia, Vancouver, Canada (A. Levin); Mount Elizabeth Novena Hospital, Singapore (A. Liew); Peking University First Hospital, Beijing (H.Z.); Chinook Therapeutics, Seattle (T.G.); Novartis, East Hanover, NJ (A. Lodha, Y.W.); Novartis, Basel, Switzerland (R.R.); and the University of Leicester, Leicester, United Kingdom (J.B.)., Lodha A; From the Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands (H.J.L.H.); the National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney (M.J.); the Division of Nephrology, University of Utah Health, Salt Lake City (D.E.K.); Stanford University, Stanford, CA (R.A.L.); the University of British Columbia, Vancouver, Canada (A. Levin); Mount Elizabeth Novena Hospital, Singapore (A. Liew); Peking University First Hospital, Beijing (H.Z.); Chinook Therapeutics, Seattle (T.G.); Novartis, East Hanover, NJ (A. Lodha, Y.W.); Novartis, Basel, Switzerland (R.R.); and the University of Leicester, Leicester, United Kingdom (J.B.)., Gray T; From the Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands (H.J.L.H.); the National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney (M.J.); the Division of Nephrology, University of Utah Health, Salt Lake City (D.E.K.); Stanford University, Stanford, CA (R.A.L.); the University of British Columbia, Vancouver, Canada (A. Levin); Mount Elizabeth Novena Hospital, Singapore (A. Liew); Peking University First Hospital, Beijing (H.Z.); Chinook Therapeutics, Seattle (T.G.); Novartis, East Hanover, NJ (A. Lodha, Y.W.); Novartis, Basel, Switzerland (R.R.); and the University of Leicester, Leicester, United Kingdom (J.B.)., Wang Y; From the Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands (H.J.L.H.); the National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney (M.J.); the Division of Nephrology, University of Utah Health, Salt Lake City (D.E.K.); Stanford University, Stanford, CA (R.A.L.); the University of British Columbia, Vancouver, Canada (A. Levin); Mount Elizabeth Novena Hospital, Singapore (A. Liew); Peking University First Hospital, Beijing (H.Z.); Chinook Therapeutics, Seattle (T.G.); Novartis, East Hanover, NJ (A. Lodha, Y.W.); Novartis, Basel, Switzerland (R.R.); and the University of Leicester, Leicester, United Kingdom (J.B.)., Renfurm R; From the Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands (H.J.L.H.); the National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney (M.J.); the Division of Nephrology, University of Utah Health, Salt Lake City (D.E.K.); Stanford University, Stanford, CA (R.A.L.); the University of British Columbia, Vancouver, Canada (A. Levin); Mount Elizabeth Novena Hospital, Singapore (A. Liew); Peking University First Hospital, Beijing (H.Z.); Chinook Therapeutics, Seattle (T.G.); Novartis, East Hanover, NJ (A. Lodha, Y.W.); Novartis, Basel, Switzerland (R.R.); and the University of Leicester, Leicester, United Kingdom (J.B.)., Barratt J; From the Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands (H.J.L.H.); the National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney (M.J.); the Division of Nephrology, University of Utah Health, Salt Lake City (D.E.K.); Stanford University, Stanford, CA (R.A.L.); the University of British Columbia, Vancouver, Canada (A. Levin); Mount Elizabeth Novena Hospital, Singapore (A. Liew); Peking University First Hospital, Beijing (H.Z.); Chinook Therapeutics, Seattle (T.G.); Novartis, East Hanover, NJ (A. Lodha, Y.W.); Novartis, Basel, Switzerland (R.R.); and the University of Leicester, Leicester, United Kingdom (J.B.).

Publikováno v: The New England journal of medicine [N Engl J Med] 2024 Oct 25. Date of Electronic Publication: 2024 Oct 25.